Tenax Therapeutics, Inc.
TENX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$1.64
KIRA · Stoqly’s AI analyst, in plain words
- Tenax Therapeutics, Inc. had $0.0M of revenue in fiscal 2025.
- Tenax Therapeutics, Inc. lost $52.6M in fiscal 2025.
Market cap
$83.4M
P/E
—
Revenue
$0.0M
Net income
−$52.6M
Free cash flow
—
Operating margin
—
Tenax Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$52.6M
No. It lost money last year.
How healthy are the accounts?
1 / 7
Weak. It passes 1 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Tenax Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- TENAX THERAPEUTICS, INC.
- CIK
- 0000034956
Tenax Therapeutics, Inc. · TENX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | — | — | $0.0M | $0.0M |
| Revenue growth | −43.8% | — | — | — | — |
| Net interest income | $0.0M | — | — | — | — |
| Operating margin | −3,636,466.7% | — | — | — | — |
| Net income | −$32.5M | $11.0M | −$7.7M | −$17.6M | −$52.6M |
| Net margin | −3,608,266.7% | — | — | — | — |
| Diluted EPS | −$1.58 | — | −$31.04 | −$1.15 | −$1.34 |
| Cash | |||||
| Cash from operations | −$10.9M | −$11.4M | −$5.9M | −$14.8M | −$35.8M |
| Capital expenditure | $0.0M | $0.0M | — | — | — |
| Free cash flow | −$10.9M | −$11.4M | — | — | — |
| FCF margin | −1,206,833.3% | — | — | — | — |
| Share count change | 98.5% | — | — | 6,048.0% | 156.8% |
| Debt and strength | |||||
| Cash and short-term investments | $5.6M | $2.1M | $9.8M | $94.9M | $97.6M |
| Shareholders' equity | $4.2M | $1.5M | $8.1M | $92.0M | $97.1M |
| Current ratio | 3.6x | 1.7x | 3.3x | 20.6x | 14.6x |
| Interest coverage | −36,364.7x | 2,512.0x | −343.1x | −847.6x | — |
| Returns and quality | |||||
| Return on equity | −732.2% | 385.1% | −160.8% | −35.2% | −55.6% |
| Return on tangible equity | −765.1% | 740.0% | −95.2% | −19.1% | −54.2% |
| Piotroski F-score | 2 | — | — | — | 1 |
| Altman Z'' | −181.1 | −252.0 | −80.7 | 14.9 | 5.2 |
Insiders bought, 12 months
$6.6M
8 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Tenax Therapeutics, Inc. · TENX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $1.64 a share, the company is worth $83.4M.
Source: SEC EDGAR XBRL filings (CIK 0000034956). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.